MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务。

PF-1355

CAS No. : 1435467-38-1

MCE 站：PF-1355

产品活性：PF-1355 是一种有效的 MPO 抑制剂，用于血管炎的研究。

研究领域：Metabolic Enzyme/Protease

作用靶点：Glutathione Peroxidase

In Vitro: In a dose-responsive fashion, PF-1355 inhibits MPO activity in phorbol ester-stimulated human neutrophils as measured by taurine chlorination (EC₅₀=1.47 μM) as well as lipopolysaccharide-treated human blood measuring residual MPO activity (EC₅₀=2.03 μM).

In Vivo: Oral administration of PF-1355 reduces plasma MPO activity, vascular edema, neutrophil recruitment, and elevates circulating cytokines. In a model of anti-glomerular basement membrane disease, formerly known as Goodpasture disease, albuminuria and chronic renal dysfunction are completely suppressed by PF-1355 treatment.

相关产品：Bioactive Compound Library Plus  |  Immunology/Inflammation Compound Library  |  Metabolism/Protease Compound Library  |  Anti-Aging Compound Library  |  Antioxidants Compound Library  |  Oxygen Sensing Compound Library  |  Anti-Cardiovascular Disease Compound Library  |  RSL3  |  ML-210  |  MPO-IN-28  |  N-Acetyl lysyltyrosylcysteine amide  |  4-Methylesculetin  |  Tinoridine hydrochloride

品牌介绍:
•   MCE (MedChemExpress) 拥有数百种全球独家化合物，我们致力于为全球科研客户提供*新*全的高品质小分子活性化合物；
•   10,000 多种高选择性抑制剂、激动剂涉及各热门信号通路及疾病领域；
•   设有专业的实验中心和严格的质控、验证体系；
•   提供 LC/MS、NMR、HPLC、手性分析、元素分析等各项质检报告，确保产品的高纯度、高品质；
•   产品的生物活性多经各国客户实验验证；
•   Nature, Cell, Science 等多种期刊及制药收录了MCE客户的科研成果；
•   专业团队跟踪*新的制药及生命科学研究进展，为您提供全球*新的活性化合物；
•   与世界各大制药公司及知名科研机构建立了长期的合作。